Continuously improving ifosfamide/mesna: A winning combination

Pediatric Blood and Cancer

Volumn 55, Issue 4, 2010, Pages 599-600

  Anderson, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; ALBUMIN; APREPITANT; DRUG METABOLITE; GRANISETRON; IFOSFAMIDE; MESNA; ANTINEOPLASTIC AGENT;

ANEMIA; BLADDER TOXICITY; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHILDHOOD CANCER; CONTINUOUS INFUSION; DRUG BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG STABILITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPOPHOSPHATEMIA; LIMB WEAKNESS; MALE INFERTILITY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NOTE; OSTEOSARCOMA; OUTPATIENT; PARESTHESIA; PEDIATRIC SARCOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN TINGLING; SLEEP DEPRIVATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; CHILD; SARCOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; HUMANS; IFOSFAMIDE; MESNA; SARCOMA;

EID: 77957094887     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22652     Document Type: Note

References (10)

1. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, et al. Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5: 1191-1198.
2. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. J Clin Oncol 2002; 20: 426-433.
3. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001; 40: 41-62.
4. Anderson P, Aguilera D, Pearson M, et al. Outpatient chemotherapy plus radiotherapy in sarcomas: Improving cancer control with radiosensitizing agents. Cancer Control 2008; 15: 38-46.
5. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100: 630-641.
6. Radford JA, Margison JM, Swindell R, et al. The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J Cancer Res Clin Oncol 1991; 117: S154-S156.
7. Priston MJ, Sewell GJ. Stability of three cytotoxic drug infusions in the Graseby 9000 ambulatory infusion pump. J Oncol Pharm Practice 1998; 4: 143-149.
8. Skubitz KM, Hamdan H, Thompson RC, Jr. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993; 72: 2963-2969.
9. Coriat R, Mir O, Camps S, Ropert S, et al. Ambulatory administration of 5-day infusion ifosfamide + mesna: A pilot study in sarcoma patients. Cancer Chemother Pharmacol 65: 491-495.
10. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer 2008; 50: 347-351.